Shanghai medicine "Malay acid innapuli film" has been reviewed.

Malay acid inapris tablets are mainly used to treat all periods of primary hypertension, renal vascular hypertension, heart failure at all levels, prevent symptomatic heart failure, prevent coronary artery ischemia in patients with left ventricle dysfunction, developed by Merck, first listed in Japan in 1986.
October 2018, Changzhou Pharmaceuticals filed an application with the State Drug Administration for a consistent evaluation of generic drugs.
2018, Changzhou Pharmaceuticals generated sales of RMB17.39 million.
As of the date of this announcement, the main manufacturers of the drug in China are Yangzijiang Pharmaceutical Group Jiangsu Pharmaceutical Co., Ltd., Shishi Pharmaceutical Group Ouyi Pharmaceutical Co., Ltd. and Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd.
as of the date of this announcement, the Company has invested about RMB 878.12 million in research and development for the consistency evaluation of the drug. according to the
IQVIA database, the drug hospital purchaseamounted rmb 199.68 million in 2018.
original title: Shanghai medicine "Malay acid innapuli tablets" through consistency evaluation.